NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RLMD

Relmada Therapeutics Inc

Jun 30 • 04:00PM ET

0.6003

Dollar change -0.0097
Percentage change -1.59	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM SAGE ACAD NBIX VKTX ITCI XENE OVID CORT BHVN

| Held by: VXF PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.50	Insider Own	19.46%	Shs Outstand	33.19M	Perf Week	-1.74%
Market Cap	19.92M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	17.86%	Shs Float	26.73M	Perf Month	-16.82%
Enterprise Value	-7.14M	PEG	-	EPS next Q	-0.46	Inst Own	25.04%	Short Float	2.60%	Perf Quarter	102.33%
Income	-75.71M	P/S	-	EPS this Y	27.17%	Inst Trans	-2.21%	Short Ratio	0.38	Perf Half Y	66.10%
Sales	0.00M	P/B	0.89	EPS next Y	48.70%	ROA	-135.09%	Short Interest	0.70M	Perf YTD	15.44%
Book/sh	0.68	P/C	0.74	EPS next 5Y	31.28%	ROE	-160.26%	52W High	4.47 -86.57%	Perf Year	-79.92%
Cash/sh	0.82	P/FCF	-	EPS past 3/5Y	28.20% 0.68%	ROIC	-337.38%	52W Low	0.24 149.71%	Perf 3Y	-96.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.10% 12.34%	Perf 5Y	-98.74%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	20.03%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-98.57%
Dividend Ex-Date	-	Quick Ratio	5.29	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.42	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.29	EPS Q/Q	20.29%	SMA20	-14.26%	Beta	0.61	Target Price	1.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	5.53%	Rel Volume	0.11	Prev Close	0.61
Employees	17	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	-52.80%	Avg Volume	1.81M	Price	0.60
IPO	Jun 20, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-20.83% -	Trades		Volume	194,611	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral	$23 → $1
Sep-17-24	Upgrade	Jefferies	Hold → Buy	$3.50 → $13
Jun-05-24	Downgrade	Goldman	Neutral → Sell	$3 → $2
Oct-14-22	Downgrade	Truist	Buy → Hold	$90 → $10
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Goldman	Buy → Neutral	$81 → $8
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform	$64 → $7
Nov-18-21	Initiated	Mizuho	Buy	$50
May-20-21	Resumed	Goldman	Buy	$78
Oct-28-20	Downgrade	Goldman	Buy → Neutral	$69 → $40
Jul-14-20	Initiated	Oppenheimer	Outperform	$75
May-04-20	Initiated	SunTrust	Buy	$75
Apr-21-20	Initiated	Goldman	Buy	$63
Jan-27-20	Initiated	Jefferies	Buy	$75
Jan-10-20	Initiated	SVB Leerink	Outperform	$50
Dec-16-19	Initiated	Guggenheim	Buy	$64

Show Previous Ratings

Jun-17-25 07:00AM	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology (GlobeNewswire)
May-13-25 09:08AM	Q1 2025 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... (GuruFocus.com)
May-12-25 04:01PM	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.05%
May-08-25 07:30AM	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire) +5.64%
01:38PM	Loading…
Apr-28-25 01:38PM	Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 (GlobeNewswire) -44.64%
Apr-27-25 09:00AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Apr-24-25 08:00AM	Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data (GlobeNewswire) +6.86%
Apr-14-25 08:41AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
07:30AM	Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Mar-28-25 07:05AM	Q4 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... (GuruFocus.com)
Mar-27-25 08:07PM	Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire)
Mar-26-25 09:00AM	Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 (GlobeNewswire)
07:30AM	Loading…
Mar-25-25 07:30AM	Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. (GlobeNewswire) +6.09%
Feb-07-25 06:46AM	Relmada acquires Tourettes therapy rights from Asarina (Pharmaceutical Technology) -9.62%
Feb-06-25 07:30AM	Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB (GlobeNewswire) -10.00%
Dec-09-24 07:30AM	Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 (GlobeNewswire) +5.14%
Dec-05-24 07:36AM	Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile (TipRanks) -28.57%
Dec-04-24 07:30AM	Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance (GlobeNewswire) -77.26%
Nov-19-24 09:00AM	Relmada Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease (GlobeNewswire)
Nov-10-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024 (Market Exclusive)
Nov-08-24 02:28AM	Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Nov-07-24 04:32PM	Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-04-24 04:30PM	Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-12-24 01:07AM	Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) (GuruFocus.com) +8.28%
01:06AM	Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares (GuruFocus.com)
Aug-12-24 09:35AM	Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
01:51PM	Loading…
Aug-08-24 01:51PM	Q2 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -29.01%
Aug-07-24 04:05PM	Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-05-24 07:30AM	Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -5.83%
Jun-18-24 08:30AM	Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry (PR Newswire)
Jun-10-24 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire) +5.76%
Jun-03-24 07:30AM	Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-11-24 08:41AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:20AM	Q1 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:55PM	RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Mar-20-24 10:27AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript (Insider Monkey) -17.41%
06:27AM	Q4 2023 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:52PM	RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
05:31PM	Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results (GuruFocus.com)
04:15PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Mar-12-24 07:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 (PR Newswire)
Mar-05-24 07:30AM	Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-01-24 03:02PM	Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares (GuruFocus.com) +16.03%
Jan-05-24 05:12PM	Health Care Roundup: Market Talk (The Wall Street Journal) +7.27%
Jan-04-24 07:30AM	Relmada Therapeutics Provides Corporate Update (PR Newswire) -31.68%
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey) +9.23%
Dec-20-23 02:39PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (ready to review) (Insider Monkey)
02:14PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Nov-10-23 01:57PM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:47PM	Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-03-23 07:30AM	Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 (PR Newswire)
Oct-11-23 08:31AM	Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023 (PR Newswire)
Oct-09-23 07:30AM	Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (PR Newswire)
Oct-06-23 07:30AM	Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress (PR Newswire)
Sep-20-23 08:30AM	Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder (PR Newswire) +6.09%
Aug-23-23 07:30AM	Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
Aug-08-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (PR Newswire) +7.09%
Aug-01-23 07:30AM	Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 (PR Newswire)
Jul-31-23 06:10AM	7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick (InvestorPlace)
Jun-08-23 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference (PR Newswire)
Jun-02-23 07:30AM	Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference (PR Newswire)
May-24-23 07:42AM	Relmada Therapeutics Insider Ups Holding By 62% During Year \ (Simply Wall St.)
07:30AM	Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting (PR Newswire)
May-11-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (PR Newswire) -6.31%
May-08-23 07:30AM	Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023 (PR Newswire) +9.94%
Apr-12-23 12:59PM	Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely? (Simply Wall St.)
Mar-27-23 07:12AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 09:08AM	Q4 2022 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results (PR Newswire)
Mar-17-23 08:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 (PR Newswire) -5.36%
Feb-27-23 09:13AM	10 Most Promising Psychedelic Stocks According To Analysts (Insider Monkey)
Feb-17-23 06:35AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the company (Simply Wall St.)
Jan-12-23 08:00AM	Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors (PR Newswire) +15.30%
Jan-09-23 08:00AM	Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer (PR Newswire)
Dec-29-22 09:11AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Call Transcript (Insider Monkey) +10.94%
Dec-15-22 06:08AM	Sergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More Shares (Simply Wall St.)
Dec-08-22 08:39AM	Relmada Therapeutics shares decline 40% on Thursday (MarketWatch) -47.84%
08:12AM	Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke (Benzinga)
Dec-07-22 04:05PM	Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (PR Newswire)
Nov-10-22 04:05PM	Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results (PR Newswire) +8.73%
Nov-08-22 04:15PM	Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 (PR Newswire)
Nov-03-22 12:24PM	We Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth Carefully (Simply Wall St.) +5.18%
Oct-20-22 11:28AM	Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More (Zacks)
Oct-14-22 12:55PM	Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study (Zacks)
11:30AM	Relmada's Trial Failure Removes Competitor Risk For This Company's Newly Launched Depression Product (Benzinga)
Oct-13-22 04:04PM	Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges (Investor's Business Daily) -79.57%
08:49AM	Relmada Stock Tumbles To 52-Week Low On Failed Depression Trial (Benzinga)
08:00AM	Relmadas stock tumbles 80% after its depressive disorder drug failed a late-stage study (MarketWatch)
07:00AM	Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder (PR Newswire)
Sep-20-22 08:30AM	Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder (PR Newswire)
Aug-14-22 10:14AM	What Type Of Shareholders Own The Most Number of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares? (Simply Wall St.)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Paul Edward	Chief Operating Officer	May 16 '25	Buy	0.43	200,000	86,060	412,295	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 19 '25	Buy	0.49	90,000	43,686	228,335	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 20 '25	Buy	0.52	60,000	31,422	288,335	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 16 '25	Buy	0.44	50,000	22,100	138,335	May 20 06:03 PM
Ence Chuck	CA and CO	May 16 '25	Buy	0.45	228,961	103,330	267,931	May 20 06:02 PM
TRAVERSA SERGIO	Chief Executive Officer	May 20 '25	Buy	0.56	147,686	82,246	734,024	May 20 06:01 PM
TRAVERSA SERGIO	Chief Executive Officer	May 16 '25	Buy	0.45	172,314	77,472	556,338	May 20 06:01 PM
TRAVERSA SERGIO	Chief Executive Officer	May 19 '25	Buy	0.50	30,000	14,994	586,338	May 20 06:01 PM
TRAVERSA SERGIO	Chief Executive Officer	Sep 11 '24	Buy	2.99	51,407	153,707	384,024	Sep 11 05:47 PM
TRAVERSA SERGIO	Chief Executive Officer	Sep 09 '24	Buy	2.71	55,579	150,619	299,603	Sep 11 05:47 PM
TRAVERSA SERGIO	Chief Executive Officer	Sep 10 '24	Buy	2.75	33,014	90,788	332,617	Sep 11 05:47 PM
CASAMENTO CHARLES J	Director	Sep 09 '24	Buy	2.56	13,000	33,280	13,000	Sep 11 05:47 PM
Shenouda Maged	Chief Financial Officer	Sep 11 '24	Buy	2.95	24,120	71,154	88,335	Sep 11 05:46 PM
Shenouda Maged	Chief Financial Officer	Sep 10 '24	Buy	2.73	21,118	57,652	64,215	Sep 11 05:46 PM
Shenouda Maged	Chief Financial Officer	Sep 09 '24	Buy	2.55	8,194	20,895	43,097	Sep 11 05:46 PM
Kelly Paul Edward	Director	Sep 09 '24	Buy	2.59	25,000	64,750	212,295	Sep 11 05:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLMD

Relmada Therapeutics Inc

Upgrade your FINVIZ experience